Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed a license and distribution agreement with Isologic Innovative Pharmaceuticals Ltd (Isologic) for the commercialisation of Telix’s investigational prostate cancer imaging agent, Illuccix^®(kit for preparation of gallium Ga-68 gozetotide injection), also known as ⁶⁸Ga-PSMA-11 injection, for the Canadian market.

Please follow the link for the entiere release

English : https://www.newswire.ca/news-releases/telix-and-isologic-sign-license-and-distribution-agreement-for-illuccix-r-for-canada-858971274.html